Mitsubishi Gas Chemical files joint nucleic acid drug patent with Veritas In Silico

Mitsubishi Gas Chemical and Veritas In Silico jointly filed a substance patent application for a nucleic acid drug titled "Nucleic acid drug and its use" (application number 2026-179989). The invention targets lncRNA H19, linked to cancer cell proliferation, invasion, metastasis and treatment resistance, and was generated using Veritas In Silico's aibVIS AI drug-discovery platform under their joint research. Mitsubishi Gas Chemical has invested in Veritas In Silico since 2017 and launched its AXELPHEX nucleic acid drug API CRDMO service in October 2025.

Key facts

Market context

Nucleic acid drugs are a class of therapeutics built from short synthetic strands of DNA or RNA that act on genetic targets, and their manufacture depends on specialized oligonucleotide synthesis, purification and contract development and manufacturing services. Demand is driven mainly by pharmaceutical developers working in oncology and rare or hard-to-treat diseases, where companies are looking for new target classes beyond small molecules and antibodies. Long non-coding RNAs such as H19 are studied as regulators of tumor growth and spread, which is why they attract interest from drug discovery teams. For chemical suppliers, moves like this matter less for near-term volumes than for the pipeline they create: a patent filing signals that a candidate may need intermediates and active pharmaceutical ingredients in later development stages, and a contract manufacturing offering gains value as more candidates move toward clinical use. Competition in this segment centers on synthesis capability, quality systems and capacity for oligonucleotide production.

Source: official release on mgc.co.jp. Summary and context written by Market Krystal.